Skip to main content
Nicole Gormley, MD, Hematology, Bethesda, MD

Nicole Jeanine Gormley MD


Division Director, FDA

Join to View Full Profile
  • 10 Center DrBldg 10Bethesda, MD 20892

  • Phone+1 301-496-9320

Dr. Gormley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Critical Care Medicine (Internal Medicine), 2008 - 2010
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2006 - 2008
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 2003 - 2006
  • The University of Toledo College of Medicine
    The University of Toledo College of MedicineClass of 2003

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2006 - 2026

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens
    Nicole J. Gormley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Effect of Cyclosporine Inhalation Solution (CIS) on Lung Function and Inflammatory Biomarkers in Patients with Hematopoietic Stem Cell Transplant (HSCT) Associated Bro...
    Nicole J. Gormley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • FDA Panel Puts PI3K Inhibitors for Blood Cancers on Notice
    FDA Panel Puts PI3K Inhibitors for Blood Cancers on NoticeApril 22nd, 2022
  • FDA’s Cancer Advisory Committee to Evaluate Safety of PI3K Inhibitors
    FDA’s Cancer Advisory Committee to Evaluate Safety of PI3K InhibitorsApril 20th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: